Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Pranita Atri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0417-0256; OpenAlex author ID A5012159690. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 7 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 20

  1. Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-ras G12D Inhibition in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.041↗
  2. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217097↗
  3. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  4. A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-23-0825↗
  5. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2022.215922↗
  6. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  7. Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2022.03.022↗
  8. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  9. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance. Co-author DOI 10.1053/j.gastro.2021.09.017↗
  10. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗
  11. Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. Co-author PMID 35141005↗
  12. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. Co-author DOI 10.1158/0008-5472.can-20-1293↗
  13. Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1591↗
  14. Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer. Co-author DOI 10.3390/cancers13040818↗
  15. Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s). Co-author DOI 10.1016/j.bbcan.2019.188318↗
  16. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1359↗
  17. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2019.03.056↗
  18. Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1. Co-author DOI 10.1053/j.gastro.2018.05.041↗
  19. Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. Co-author DOI 10.18632/oncotarget.23644↗
  20. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Co-author DOI 10.18632/oncotarget.25036↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 20 shared papers, 2018–2026 · strength 2.59
  2. Ashu Shah · 8 shared papers, 2021–2024 · strength 1.21
  3. Moorthy Palanimuthu Ponnusamy · 9 shared papers, 2018–2024 · strength 1.19
  4. Lynette M. Smith · 10 shared papers, 2018–2024 · strength 1.17
  5. Jesse L. Cox · 7 shared papers, 2021–2026 · strength 1.17
  6. Sanchita Rauth · 8 shared papers, 2018–2024 · strength 1.02
  7. Sushil Kumar K · 8 shared papers, 2018–2024 · strength 1.01
  8. Satyanarayana Rachagani · 8 shared papers, 2018–2024 · strength 0.86
  9. Koelina Ganguly · 5 shared papers, 2019–2024 · strength 0.68
  10. Sukhwinder Kaur · 6 shared papers, 2019–2022 · strength 0.67
  11. Palanisamy Nallasamy · 4 shared papers, 2021–2026 · strength 0.66
  12. Maneesh Jain · 5 shared papers, 2020–2024 · strength 0.63
  13. Saravanakumar Marimuthu · 4 shared papers, 2022–2026 · strength 0.60
  14. Parthasarathy Seshacharyulu · 5 shared papers, 2018–2024 · strength 0.59
  15. Rama Krishna Nimmakayala · 5 shared papers, 2018–2022 · strength 0.53
  16. Rakesh Bhatia · 4 shared papers, 2020–2022 · strength 0.48
  17. Namita Bhyravbhatla · 3 shared papers, 2022–2026 · strength 0.48
  18. Paul M. Grandgenett · 4 shared papers, 2019–2022 · strength 0.48
  19. Joseph Carmicheal · 4 shared papers, 2019–2024 · strength 0.47
  20. Sushil Kumar · 3 shared papers, 2021–2024 · strength 0.43
  21. Michael Anthony Hollingsworth · 3 shared papers, 2021–2022 · strength 0.39
  22. Sophia G. Kisling · 2 shared papers, 2023–2024 · strength 0.39
  23. Rahat Jahan · 3 shared papers, 2019–2024 · strength 0.39
  24. Geoffrey A. Talmon · 4 shared papers, 2018–2022 · strength 0.38
  25. Kavita B. Mallya · 3 shared papers, 2022 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.